MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Post-Election Commentary from Medtech Executives

Post-Election Commentary from Medtech Executives
What do medical device executives have to say about expected changes to the healthcare industry under the incoming Trump administration? Here's what five medtech leaders are saying about the potential for impact to their businesses.

What do medical device executives have to say about expected changes to the healthcare industry under the incoming Trump administration? Here's what five medtech leaders are saying about the potential for impact to their businesses.

More than a week has passed since the elections and medtech executives have had some time to consider what President-elect Trump and the new Congress will mean for their business.

Full or partial repeal of the Affordable Care Act is on the table, as is permanent elimination of the medical device excise tax and the possibility of a corporate tax repatriation holiday. What does this mean for device sales, investment in research and development, and the shift toward value-based healthcare?

A few leaders have started to make public comments on the topic. Read on for early comments from these five executives at major medtech companies.

 

Take the Medical Innovation Tours during the BIOMEDevice San Jose Conference and Expo, December 7-8.

[Image courtesy of SIRA ANAMWONG/FREEDIGITALPHOTOS.NET]

 
Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish